News articles about Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries Limited earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.9677724919758 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news articles that may have effected Accern’s scoring:

A number of research analysts have weighed in on the stock. HSBC Holdings plc lowered shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “reduce” rating in a research note on Tuesday. Mizuho reissued a “hold” rating and issued a $15.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, October 30th. Jefferies Group LLC reissued a “hold” rating and issued a $26.00 target price (down from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Susquehanna Bancshares Inc decreased their target price on shares of Teva Pharmaceutical Industries Limited from $20.00 to $14.00 and set a “positive” rating on the stock in a research note on Monday. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $28.00 target price (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Six research analysts have rated the stock with a sell rating, eighteen have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and an average price target of $24.18.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at $12.40 on Tuesday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The company has a market cap of $11,582.40, a price-to-earnings ratio of 2.63 and a beta of 0.52. Teva Pharmaceutical Industries Limited has a 12 month low of $10.85 and a 12 month high of $42.90.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a dividend of $0.085 per share. The ex-dividend date is Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.74%. Teva Pharmaceutical Industries Limited’s payout ratio is currently -15.80%.

WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Given News Impact Rating of 0.12” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-given-news-impact-rating-of-0-12/1684839.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.